abstract |
The present invention relates to a novel natural killer cell line and a use thereof, more particularly, to a cell line which is positive for CD2, CD11a, CD25, CD45, CD54, CD56 and HLA-DR; And a novel natural killer cell line which is negative for CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ and TCRγδ and a pharmaceutical composition for treating cancer comprising the same. |